ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 292

Derivation of a National Rheumatoid Arthritis Cohort in the Veterans Health Administration and Validation with the Veterans Affairs Rheumatoid Arthritis Registry

Bryant R. England1, Punyasha Roul2, Brian Sauer3, Shaobo Pei4, Grant W. Cannon5, Joshua Baker6 and Ted R. Mikuls7, 1Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 4University of Utah, Salt Lake City, UT, 5Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 6Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, 7VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Administrative databases and rheumatoid arthritis (RA), Validity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Health Services Research Poster I – ACR/ARHP

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 9:00AM-11:00AM

Background/Purpose: The Veterans Health Administration health system represents the largest integrated healthcare system in the U.S. and maintains robust administrative and clinical data that can facilitate outcomes research of chronic diseases.  Our objective was to compare the ability of a combination of available Veterans Affairs (VA) data sources to define a national cohort of rheumatoid arthritis (RA) patients and validate these potential cohorts using the Veterans Affairs Rheumatoid Arthritis (VARA) Registry.

Methods: We queried national VA data in the Corporate Data Warehouse within the VA Informatics and Computing Infrastructure from 2000 through April 1, 2018. We collected outpatient and inpatient diagnostic codes, diagnostic codes from non-VA providers, outpatient medications and IV infusions, non-VA medications, provider specialty, autoantibody status, and corresponding dates. We tested the performance of administrative-based algorithms with varying requirements for RA classification. We characterized cohort membership by DMARD use and autoantibody status, and then calculated the sensitivity of each algorithm in VARA where all participants (n= 2640) fulfilled 1987 ACR RA Criteria.

Results: Using an RA algorithm based only on diagnostic codes, we identified 121,946 unique patients in the VA (Table 1). More stringent algorithms requiring rheumatologist diagnosis, DMARD use, exclusion of other rheumatic diseases, and/or incorporating autoantibody results reduced the cohort size (60,845 in the most stringent algorithm). The application of additional criteria had a limited impact on the sensitivity, with the most stringent algorithm identifying 94.5% of VARA participants. The proportion receiving a DMARD consistently increased with more restrictive algorithms in the national cohort (Table 2). The most restrictive algorithm yielded 97.6% with DMARD use (69.3% for MTX). Similarly, autoantibody positivity increased with greater stringency of the algorithm with a frequency of anti-CCP positivity ranging from 56.1% in criteria using only diagnostic codes to 64.6%.

Conclusion: Administrative-based algorithms are highly sensitive for defining a national cohort of VA patients with RA.  The characteristics of this newly assembled national cohort reflect those of an established RA registry with respect to DMARD use, suggesting reasonable specificity. Greater autoantibody positivity in VARA registry may be due to channeling of seropositive subjects into registry participation.


Disclosure: B. R. England, None; P. Roul, None; B. Sauer, None; S. Pei, None; G. W. Cannon, Amgen Inc., 2; J. Baker, Corrona, Bristol Myers Squibb, 5; T. R. Mikuls, BMS, Ironwood, Horizon, 2,Pfizer, Inc., 5.

To cite this abstract in AMA style:

England BR, Roul P, Sauer B, Pei S, Cannon GW, Baker J, Mikuls TR. Derivation of a National Rheumatoid Arthritis Cohort in the Veterans Health Administration and Validation with the Veterans Affairs Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/derivation-of-a-national-rheumatoid-arthritis-cohort-in-the-veterans-health-administration-and-validation-with-the-veterans-affairs-rheumatoid-arthritis-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/derivation-of-a-national-rheumatoid-arthritis-cohort-in-the-veterans-health-administration-and-validation-with-the-veterans-affairs-rheumatoid-arthritis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology